| | Normal ducts % | Low-grade PanINs % | High-grade PanINs % |
|---|
Ctr (n = 11) | 68.0 ± 7.3 | 26.6 ± 5.4 | 5.4 ± 5.6 |
Diab (n = 3) | 31.7 ± 10.5 ** | 42.0 ± 6.6 ** | 26.3 ± 14.22 ** |
Diab + FL (n = 9) | 51.3 ± 5.9 ** †† | 37.4 ± 7.3 ** | 11.2 ± 4.3 †† |
Ctr + FL (n = 8) | 77.0 ± 6.2 * †† | 20.4 ± 5.6 * †† | 2.6 ± 1.5 †† |
STZ-non-Diab (n = 8) | 61.6 ± 9.7 †† | 32.4 ± 7.4 | 6.6 ± 5.2 †† |
- PanIN grading in control (Ctr), diabetic (Diab), Diab treated with FL-926-16 (Diab+FL), Ctr treated with FL-926-16 (Ctr + FL) and streptozotocin-treated non-diabetic (STZ-non-Diab) KCM mice free of invasive pancreatic cancer as attested by histology at the end of the study (16 weeks of diabetes, 22 weeks of age). KCM = LSL-KrasG12D/+; Pdx-1-Cre; MITO. **P < 0.01 and *P < 0.05 vs Ctr; ††P < 0.01 vs Diab. Statistical significance between groups for Normal ducts, Low-grade (PanIN-1A/B) and High-grade (PanIN-2/3) dysplastic ducts was calculated using one-way ANOVA followed by the Student-Newman-Keuls test for multiple comparisons
